GlassScriptPhysician profile
Mathias Zemel
NPI 1649381310
$664.63
in general payments reported to CMS, 2019-2025
13 companies · $321 in 2025
The $321 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.99 · 2020: $59.63 · 2021: $20.57 · 2022: $14.73 · 2024: $159 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $267 · Food and Beverage: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $266.97 |
| Food and Beverage | $213.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $266.97 | 2024-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $95.09 | 2019-2025 | |
| Abbvie INC. | $89.65 | 2020-2025 | |
| Pfizer INC. | $67.01 | 2019-2025 | |
| Sandoz INC. | $18.58 | 2020 | |
| Botanix Sb INC | $18.50 | 2025 | Sofdra |
| Galderma Laboratories, L.P. | $18.28 | 2025 | Nemluvio |
| Leo Pharma INC. | $18.13 | 2025 | Spevigo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.62 | 2025 | Spevigo |
| Celgene Corporation | $15.00 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.21 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.15 | 2024 | Sotyktu |
| Lilly USA, LLC | $13.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mathias Zemel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.